Company intelligence / Profile preview
Cypralis
Cambridge, England, United Kingdomcypralis.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Cypralis has developed novel small molecule cyclophilin inhibitors. Its lead candidate, CC‑4066, has completed Phase 1 clinical trials for the prevention and treatment of acute kidney injury associated with major surgery. The company is also advancing preclinical programs targeting neurodegeneration and other indications by developing brain‑penetrant cyclophilin D inhibitors.
- Therapeutic areas
- GastroenterologyNeurologyNephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Farsight Medical Technology (Shanghai) CO., Ltd. – for preclinical and clinical development in China
Beyond the preview
Go deeper on Cypralis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cypralis.